Cleveland Clinic Main Campus, Mail Code A90, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Curr Rheumatol Rep. 2010 Dec;12(6):420-8. doi: 10.1007/s11926-010-0136-8.
This review focuses on vasculitides with prominent pulmonary manifestations and discusses key contributions from the recent literature. Pulmonary vasculitis should be considered when clinical findings include alveolar hemorrhage, nodular and cavitary lung disease, airway stenosis, pulmonary artery aneurysms, or pulmonary artery stenosis. The differential diagnostic considerations for common clinical presentations of vasculitis in the lung are important, and several recent additions are discussed. Treatment for established pulmonary vasculitis is effective and has decreased the morbidity and mortality associated with these diseases while introducing an increased risk of infectious complications. Advances in immunosuppressive therapy have improved treatment of refractory disease and are likely to change initial treatment strategies in the future.
这篇综述重点关注伴有明显肺部表现的血管炎,并讨论了近期文献中的重要贡献。当临床发现包括肺泡出血、结节和空洞性肺疾病、气道狭窄、肺动脉瘤或肺动脉狭窄时,应考虑肺部血管炎。常见肺部血管炎临床表现的鉴别诊断考虑很重要,讨论了最近的一些新增内容。既定的肺部血管炎的治疗是有效的,降低了与这些疾病相关的发病率和死亡率,同时增加了感染并发症的风险。免疫抑制治疗的进展改善了难治性疾病的治疗,并且可能会改变未来的初始治疗策略。